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Introduction:	  Pharmacokinetic	  modeling	  of	  contrast	  uptake	  by	  Dynamic-­‐Contrast	  
Enhanced	  Magnetic	  Resonance	  Imaging	  studies	  has	  shown	  potential	  to	  predict	  the	  
pathologic	  response	  to	  neoadjuvant	  therapy	  in	  breast	  cancer	  patients	  via	  several	  
small	  studies.	  We	  will	  attempt	  to	  prospectively	  validate	  the	  performance	  of	  several	  
previously	  published	  criteria	  in	  women	  undergoing	  neoadjuvant	  therapy	  with	  
bevacizumab	  or	  trastuzumab.	  
Methods:	  11	  patients	  underwent	  dynamic	  contrast	  enhanced	  magnetic	  resonance	  
imaging	  both	  before	  and	  after	  receiving	  one	  cycle	  of	  trastuzumab	  or	  bevacizumab	  
neoadjuvant	  chemotherapy	  for	  a	  primary	  breast	  lesion	  of	  greater	  than	  two	  
centimeters.	  By	  abstracting	  pharmacokinetic	  parameters	  (Ktrans)	  from	  each	  study,	  
predictions	  for	  therapeutic	  response	  based	  on	  previously	  published	  criteria	  (Ah-­‐See	  
and	  Yu	  utilize	  a	  threshold	  for	  percentage	  change	  in	  median	  Ktrans;	  Padhani,	  a	  
percentage	  change	  in	  Ktrans	  range)	  were	  compared	  with	  the	  response	  by	  pathology	  
acquired	  after	  completion	  of	  neoadjuvant	  therapy.	  
Results:	  7	  patients	  were	  able	  to	  successfully	  complete	  imaging	  at	  the	  two	  requisite	  
time	  points.	  All	  utilized	  criteria	  correctly	  identified	  5/5	  non-­‐responders;	  the	  Ah-­‐See	  
and	  Padhani	  criteria	  were	  able	  to	  identify	  1/2	  positive	  responders;	  and	  the	  Yu	  
criterion	  identified	  0/2	  positive	  responders.	  
Discussion:	  The	  efficacy	  of	  the	  Ah-­‐See	  and	  Padhani	  criteria	  identify	  responders	  and	  
non-­‐responders	  equally	  well.	  Due	  to	  the	  Padhani	  criterion’s	  susceptibility	  to	  noise,	  
however,	  it	  is	  likely	  that	  Ah-­‐See	  would	  outperform	  Padhani	  on	  a	  larger	  cohort.
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Introduction	  
The	  non-­‐invasive	  qualification	  and	  quantification	  of	  neoplastic	  lesions	  poses	  
obvious	  benefits	  to	  patient	  care.	  Unfortunately,	  while	  there	  exist	  imaging	  modalities	  
suited	  to	  qualifying	  tumor	  characteristics,	  obtaining	  clinically	  relevant	  measures	  of	  
malignancy	  often	  requires	  physical	  sampling	  for	  ex-­‐vivo	  pathological	  evaluation	  in	  
addition	  to	  any	  imaging.	  As	  new	  anti-­‐cancer	  agents	  whose	  primary	  effect	  may	  not	  
initially	  be	  cytolysis	  become	  increasingly	  common	  in	  clinical	  practice,	  the	  
development	  of	  non-­‐invasive	  staging	  techniques	  that	  investigate	  histologic	  or	  
metabolic	  features	  not	  traditionally	  appreciated	  via	  anatomical	  imaging	  becomes	  
necessary.	  This	  study	  will	  examine	  one	  such	  proposed	  imaging	  modality:	  
pharmacokinetic	  (PK)	  modeling	  of	  Dynamic	  Contrast-­‐Enhanced	  Magnetic	  
Resonance	  Imaging	  (DCE-­‐MRI).	  	  In	  particular,	  DCE-­‐MRI	  will	  be	  used	  to	  evaluate	  the	  
response	  of	  patients	  with	  breast	  cancer	  to	  the	  neoadjuvant	  therapy	  with	  the	  
antiangiogenic	  agents	  bevacizumab	  and	  trastuzumab.	  
	  
Clinically	  evaluating	  anti-­‐angiogenesis	  agents	  in	  breast	  cancer:	  the	  need	  for	  DCE-­‐MRI	  
Anti-­‐angiogenesis	  agents	  like	  bevacizumab	  are	  	  recombinant	  humanized	  
monocolonal	  antibody	  that	  blocks	  the	  effects	  Vascular	  Endothelial	  Growth	  Factor	  
(VEGF).	  Bavacizumab’s	  pharmacologic	  mechanism	  involves	  binding	  to,	  and	  thus	  
inhibiting,	  the	  cellular	  receptors	  of	  VEGF.	  VEGF,	  itself,	  is	  a	  potent	  inducer	  of	  many	  
effects	  thought	  to	  be	  important	  to	  the	  progression	  of	  cancer,	  including	  mitogenic	  
and	  prosurvival	  functions	  on	  vascular	  endothelial	  cells;	  angiogenesis;	  and	  induction	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of	  the	  formation	  of	  fenestrations	  in	  the	  endothelial	  lining	  of	  vessels	  1.	  To	  that	  end,	  
initial	  animal	  studies	  of	  bevacizumab	  have	  demonstrated	  in-­vivo	  inhibition	  of	  tumor	  
growth	  in	  mice	  2,	  an	  effect	  which	  has	  been	  replicated	  in	  humans	  in	  many	  different	  
solid	  tumor	  types	  3-­‐6.	  	  
	  
Breast	  cancer	  presents	  a	  particularly	  attractive	  target	  for	  bevacizumab	  because	  
many	  of	  its	  histologic	  subtypes	  have	  been	  shown	  to	  over-­‐express	  the	  VEGF	  receptor	  
7	  and	  indeed,	  studies	  have	  indicated	  the	  prognostic	  value	  of	  VEGF	  expression	  in	  
response	  to	  therapy	  8,9.	  Accordingly,	  three	  large	  randomized	  controlled	  trials	  have	  
demonstrated	  that	  the	  addition	  of	  bevacizumab	  to	  selected	  first-­‐line,	  small-­‐
molecule-­‐based	  chemotherapies	  increases	  the	  progression-­‐free	  survival	  of	  certain	  
patients	  with	  breast	  cancer	  10-­‐12.	  Interestingly,	  this	  benefit	  to	  progression	  free	  
survival	  interval	  did	  not	  correspond	  with	  an	  increase	  in	  overall	  survival	  in	  the	  
studies.	  	  This	  discordance	  has	  led	  to	  bevacizumab’s	  disapproval	  for	  use	  as	  part	  of	  
the	  primary	  chemotherapeutic	  regimen	  in	  breast	  cancer	  via	  the	  United	  States	  Food	  
and	  Drug	  Administration.	  It	  should	  be	  noted,	  however,	  that	  these	  large	  studies	  were	  
designed	  and	  conducted	  according	  to	  long-­‐established	  and	  familiar	  criteria	  for	  
measuring	  outcome.	  As	  will	  be	  discussed,	  these	  measurements	  do	  not	  directly	  
quantify	  the	  physiologic	  action	  of	  agents	  such	  as	  bevacizumab.	  
	  
There	  exist	  two	  classification	  schemes	  accepted	  by	  the	  Food	  and	  Drug	  
Administration	  for	  the	  measurement	  and	  reporting	  of	  tumor	  response	  to	  therapy	  
during	  clinical	  trials:	  the	  world	  health	  organization	  guidelines	  (WHO)13	  and	  the	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more	  recently	  developed	  Response	  Evaluation	  Criteria	  in	  Solid	  Tumors	  (RECIST)14.	  
Both	  WHO	  and	  RECIST	  guidelines	  define	  surrogate	  clinical	  endpoints	  such	  as	  
response	  and	  progression	  free	  survival	  based	  on	  serial	  	  changes	  in	  tumor	  size.	  .	  	  
Both	  utilize	  thresholds	  of	  percentage	  change	  of	  the	  largest-­‐measured	  diameter	  
(two-­‐dimensional	  in	  the	  case	  of	  WHO,	  and	  one	  dimensional	  in	  the	  case	  of	  RECIST)	  to	  
classify	  disease	  as	  progressive,	  stable,	  or	  a	  partial	  responder	  (note	  that	  complete	  
response	  is	  also	  defined,	  but	  as	  the	  absence	  of	  apparent	  disease).	  Such	  schemes	  are	  
less	  than	  ideal	  for	  the	  evaluation	  of	  anti-­‐angiogenic	  agents	  such	  as	  bevacizumab,	  
which	  are	  thought	  to	  be	  cytostatic15	  and	  may	  not	  result	  in	  immediate	  tumor	  
shrinkage.	  Thus,	  bevacizumab’s	  efficacy	  may	  not	  be	  well	  reflected	  in	  the	  traditional	  
size-­‐based	  endpoints	  incorporated	  into	  its	  clinical	  trials	  to	  date.	  
	  
The	  need	  for	  a	  well-­‐tailored,	  non-­‐invasive	  means	  for	  detecting	  the	  activity	  of	  anti-­‐
angiogenic	  agents	  such	  as	  bevacizumab	  goes	  beyond	  the	  potential	  for	  higher	  quality	  
research	  design.	  Indeed,	  as	  neoadjuvant	  therapy	  has	  become	  increasingly	  utilized	  in	  
breast	  cancer	  16,	  the	  determination	  of	  a	  given	  patient’s	  pathological	  response	  early	  
in	  their	  course	  of	  therapy	  is	  important	  as	  it	  bears	  prognostic	  significance	  and	  may	  
influence	  outcome17.	  	  Interestingly,	  a	  potentially	  clinically	  relevant	  pathological	  
response	  to	  bevacizumab	  may	  be	  detected	  as	  early	  as	  48	  hours	  after	  the	  initiation	  of	  
therapy18.	  Therefore,	  while	  it	  appears	  to	  be	  possible	  to	  gauge	  a	  patient’s	  response	  to	  
therapy	  with	  anti-­‐angiogenic	  agents,	  to	  investigate	  and	  potentially	  utilize	  them	  in	  
the	  neoadjuvant	  role,	  one’s	  current	  options	  for	  clinical	  assessment	  are	  less	  than	  
ideal:	  either	  subject	  the	  patient	  to	  invasive	  pathological	  biopsy	  or	  rely	  on	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established	  size-­‐based	  biomarkers	  that	  may	  not	  strongly	  correlate	  with	  in-­vivo	  
activity.	  
	  
This	  begs	  the	  question:	  if	  the	  metrics	  traditionally	  utilized	  to	  evaluate	  cytotoxic	  
chemotherapeutic	  agents	  are	  potentially	  inadequate	  to	  evaluate	  anti-­‐angiogenic	  
agents,	  are	  there	  other	  more	  effective	  imaging	  biomarkers?	  One	  of	  the	  most	  
promising	  imaging	  biomarkers	  is	  DCE-­‐MRI19.	  This	  study	  will	  attempt	  to	  further	  
evaluate	  DCE-­‐MRI’s	  efficacy	  in	  this	  role.	  
	  
DCE-­‐MRI	  and	  Pharmacokinetic	  Modeling	  
The	  DCE-­‐MRI	  moniker	  encompasses	  a	  wide	  range	  of	  magnetic	  resonance	  imaging	  
study	  designs.	  It	  has	  been	  employed	  to	  characterize	  lesions	  of	  many	  different	  
histologic	  types	  including:	  breast,	  prostate20,	  brain21,	  liver22,	  and	  cervix23	  among	  
others.	  Despite	  the	  variety	  of	  pathology	  surveyed,	  each	  imaging	  study	  incorporates	  a	  
very	  simple	  mechanism:	  inject	  an	  extracellular	  contrast	  agent	  during	  MR	  signal	  
acquisition	  so	  that,	  in	  the	  completed	  study,	  disparate	  phases	  of	  contrast	  wash-­‐in	  and	  
washout	  can	  be	  evaluated	  with	  some	  sort	  of	  analysis.	  
	  
In	  its	  basic	  implementation,	  DCE-­‐MRI	  is	  commonly	  used	  as	  a	  tool	  for	  evaluating	  	  
solid	  organ	  masses..	  For	  example,	  	  the	  diagnosis	  of	  several	  common	  liver	  lesions	  can	  
be	  made	  based	  on	  a	  lesion’s	  appearance	  on	  images	  obtained	  at	  three	  specific	  time	  
points	  	  following	  the	  administration	  of	  a	  CT	  or	  MRI	  contrast	  agent.	  	  	  Focal	  nodular	  
hyperplasia	  enhances	  briskly	  in	  the	  arterial	  phase	  and	  then	  becomes	  iso-­‐
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intense/iso-­‐dense	  to	  the	  liver	  parenchyma	  on	  delayed	  images.	  	  Hepatic	  
hemangiomas	  display	  peripheral,	  nodular,	  discontinuous	  enhancement	  in	  the	  
arterial	  phase	  and	  gradually	  fill	  with	  contrast	  at	  more	  delayed	  time	  points.	  	  
Hepatocellular	  carcinoma	  enhances	  briskly	  in	  the	  artierial	  phase	  and	  then	  becomes	  
hypo-­‐dense/hypo-­‐intense	  to	  the	  liver	  parenchyma	  on	  delayed	  images.	  	  The	  
subjective	  evaluation	  of	  a	  lesion’s	  enhancement	  characteristics	  over	  time	  is	  the	  
simplest	  form	  of	  DCE-­‐MRI.	  	  	  	  	  	  
	  
A	  semi-­‐quantitative	  example	  of	  DCE-­‐MRI	  is	  used	  in	  the	  diagnosis	  of	  breast	  cancer.	  	  
Early	  investigators	  evaluated	  contrast	  uptake	  and	  washout	  in	  clinically	  suspicious	  
breast	  lesions24.	  In	  their	  analysis	  of	  signal	  intensity	  curves	  obtained	  from	  nine	  time	  
points	  approximately	  forty-­‐seconds	  apart	  they	  stratified	  the	  resulting	  time-­‐intensity	  
shape	  following	  bolus	  arrival	  into	  one	  of	  the	  three	  classes	  of	  form	  demonstrated	  in	  
Figure	  1:	  uptake,	  plateau,	  and	  washout.	  Through	  this,	  they	  were	  able	  to	  show	  that	  
malignant	  tumors	  were	  more	  likely	  to	  enhance	  and	  then	  de-­‐enhance	  (consistent	  
with	  the	  washout	  curve)where-­‐as	  benign	  lesions	  tended	  to	  enhance	  progressively	  
(consistent	  with	  the	  continued	  uptake	  curve).	  (p<.001,	  sensitivity	  91%,	  specificity	  
83%).	  	  Further	  investigations	  would	  confirm	  this	  trend	  in	  morphology25,26,	  though	  
with	  insufficient	  specificity	  to	  be	  useful	  in	  confidently	  distinguishing	  benign	  from	  
malignant	  breast	  tissue.	  Nevertheless,	  the	  current	  standard	  of	  care	  in	  breast	  MRI	  is	  
to	  obtain	  high	  spatial	  resolution	  images	  of	  the	  breast	  before	  contrast,	  during	  the	  
first	  pass	  arterial	  phase,	  and	  then	  again	  5-­‐6	  minutes	  later	  and	  analyze	  the	  resulting	  
signal	  enhancement	  curve.	  	  	  This	  is	  a	  semi-­‐quantitative	  example	  of	  DCE-­‐MRI.	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Figure1	  Diagrammatic	  representation	  of	  the	  three	  categories	  of	  signal	  intensity	  (SI)	  curves	  noted	  after	  
initial	  upstroke	  from	  the	  bolus	  (dashed	  line	  marks	  the	  end	  of	  this	  period):	  continued	  uptake,	  plateau,	  
and	  washout.	  
	  
Multiple	  strategies	  to	  quantify	  curve	  morphology	  have	  been	  proposed	  and	  vary	  from	  
measuring	  the	  initial	  slope	  of	  the	  curve27,	  to	  finding	  the	  area	  under	  the	  curve	  after	  
some	  elapsed	  time	  period28,	  to	  some	  of	  the	  approaches	  discussed	  in	  greater	  detail	  in	  
this	  paper.	  What	  these	  methods	  have	  in	  common	  is	  that	  they	  attempt	  to	  capture	  the	  
pharmacokinetic	  behavior	  of	  contrast	  as	  it	  diffuses	  into	  normal	  and	  pathologic	  
tissues.	  For	  instance,	  one	  such	  method	  -­‐-­‐	  signal	  enhancement	  ratio	  (SER)	  -­‐-­‐	  is	  
calculated	  by	  measuring	  the	  signal	  in	  a	  lesion	  at	  three	  different	  time	  points	   	  
(corresponding	  to	  pre-­‐bolus	  administration,	  estimated	  peak-­‐signal	  during	  the	  first	  
pass	  arterial	  phase,	  and	  after	  enough	  time	  has	  passed	  to	  reach	  steady	  state,	  
respectively)	  29.	  SER	  is	  calculated	  as	   .	  	  	  High	  SER	  values	  correspond	  to	  tumors	  
that	  enhance	  briskly	  and	  then	  de-­‐enhance.	  	  Low	  SER	  values	  correspond	  to	  tumors	  
that	  either	  show	  low	  levels	  of	  initial	  enhancement	  or	  progressive	  delayed	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enhancement.	  	  SER	  has	  been	  studied	  in	  a	  limited	  population	  of	  breast	  cancer	  
patients	  as	  a	  predictor	  of	  resurrence	  following	  chemotherapy.	  Tumors	  with	  large	  
areas	  of	  increased	  SER	  were	  more	  likely	  to	  recur	  following	  chemotherapy	  than	  
tumors	  with	  low	  SER30.	  However,	  its	  accuracy	  in	  that	  study	  (75%	  correctly	  
identified,	  but	  only	  35%	  correctly	  identified	  before	  chemotherapy)	  leaves	  much	  to	  
be	  desired	  if	  it	  is	  to	  be	  employed	  as	  tool	  for	  clinical	  decision	  making.	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More	  rigorous	  attempts	  at	  qualitatively	  analyzing	  time-­‐enhancement	  curves	  involve	  
the	  use	  of	  true	  pharmacokinetic	  models.	  	  The	  most	  popular	  model	  was	  first	  
described	  by	  Tofts	  et	  al	  and	  variants	  of	  this	  model	  are	  recommended	  by	  the	  National	  
Cancer	  Institute	  in	  the	  US	  and	  the	  Pharmacodynamic/Pharmacokinetic	  
Technologies	  Advisory	  Committee	  in	  the	  United	  Kingdom	  whenever	  analysis	  of	  
DCE-­‐MRI	  is	  to	  be	  used	  as	  an	  imaging	  biomarker31.	  	  The	  Tofts	  model	  is	  a	  simple	  two	  
compartmental	  model	  diagrammed	  in	  Figure	  2.	  In	  it,	  contrast	  is	  introduced	  into	  the	  
blood	  plasma	  (compartment	  #1)	  and	  is	  either	  excreted	  by	  the	  kidneys	  at	  a	  
concentration-­‐dependent	  rate	  k2	  or	  leaks	  across	  a	  vascular	  barrier	  into	  a	  tumor	  
tissue	  (compartment	  #2)	  at	  a	  concentration-­‐dependent	  rate	  k1.	  	  	  In	  this	  model,	  the	  
contrast	  agent	  only	  has	  access	  to	  the	  extracellular	  space	  of	  the	  tumor	  (i.e.	  the	  
contrast	  agent	  does	  not	  actually	  enter	  into	  cells)	  ,	  so	  the	  extracellular	  fraction	  of	  the	  
tumor	  becomes	  an	  explicit	  subcomponent	  of	  the	  tissue	  compartment.	  	  If	   	  
represents	  the	  fraction	  of	  tumor	  that	  is	  extracellular	  space	  then	  the	  relationship	  
between	  the	  concentration	  of	  contrast	  in	  the	  tissue	  compartment	  ( )	  and	  its	  
extracellular	  subspace	  ( )	  is	  
	   	   (1)	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Figure	  2	  The	  Tofts	  Model.	  A	  two	  compartmental	  model	  is	  shown	  where	  concentration	  of	  contrast	  in	  the	  
plasma	  compartment	  is	  Cp(t),	  and	  the	  tissue	  compartment	  is	  Ct(t).	  Note	  that	  the	  fraction	  of	  the	  tissue	  
compartment’s	  volume	  that	  is	  accessible	  to	  contrast	  (ve)	  is	  also	  diagrammed,	  the	  extracellular	  sub-­
compartment	  and	  it’s	  concentration	  of	  contrast	  is	  given	  by	  Ce(t).	  k1	  represents	  the	  rate	  constant	  
governing	  concentration-­dependent	  movement	  of	  plasma	  between	  tumor	  and	  plasma,	  Ktrans	  between	  
the	  extracellular	  sub-­compartment,	  and	  k2	  the	  rate	  of	  renal	  excretion.	  
	  
According	  to	  Tofts,	  the	  total	  amount	  of	  contrast	  in	  tissue	  is	  therefore	  given	  as	  
	  where	   	  is	  the	  total	  volume	  of	  the	  tumor.	  This	  amount	  is	  assumed	  to	  
change	  proportionately	  to	  the	  difference	  in	  contrast	  concentrations	  between	  the	  
extracellular	  space	  and	  plasma	  according	  to	  the	  following	  differential	  equation	  
	  
	   (2)	  
where	  S	  is	  the	  total	  surface	  area	  of	  the	  microvasculature	  within	  the	  tumor	  and	  P	  is	  
the	  permeability	  of	  the	  tumor	  capillaries.	  	  By	  defining	   	  as	  the	  volume	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In	  this	  setting,	  Ktrans	  represents	  the	  rate	  constant	  for	  contrast	  flow	  across	  the	  
capillaries	  into	  the	  tumor	  (normalized	  to	  tumor	  volume),	  and	  kep	  represents	  the	  rate	  
constant	  for	  contrast	  passage	  from	  the	  tumor	  back	  into	  the	  capillaries.	  When	  
combined	  with	  initial	  conditions	   ,	  this	  differential	  equation	  has	  an	  
implicit	  solution,	  
	  
	   (3)	  
Equation	  (3)	  provides	  a	  highly	  useful	  interpretation:	  the	  concentration	  of	  contrast	  in	  
tissue	  can	  be	  broken	  into	  two	  independent	  functions.	  One,	   ,	  can	  be	  thought	  
of	  as	  a	  transfer	  function	  describing	  the	  passage	  of	  contrast	  from	  the	  vasculature	  into	  
the	  tumor.	  	  This	  transfer	  function	  is	  convoluted	  with	  Cp(t)	  which	  describes	  the	  
concentration	  of	  contrast	  in	  plasma,	  referred	  to	  in	  the	  literature	  as	  the	  arterial	  input	  
function	  (AIF).	  	  
	  
The	  original	  Tofts	  model	  defines	  a	  particular	  AIF	  according	  to	  the	  following	  
equation:	  
	   	   (4)	  
Parsing	  the	  bi-­‐exponential	  decay	  in	  equation	  (4)	  yields	  that	  –	  according	  to	  the	  Tofts	  
model	  as	  diagrammed	  in	  Figure	  1	  –	  the	  concentration	  of	  plasma	  contrast	  is	  
governed	  by	  a	  term	  representing	  the	  movement	  of	  contrast	  out	  of	  plasma	  and	  into	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tissue,	  as	  well	  as	  a	  second	  term	  which	  governs	  the	  slow	  dissipation	  of	  contrast	  via	  
renal	  excretion.	  By	  substituting	  equation	  (4)	  into	  equation	  (3)	  and	  holding	  all	  
parameters	  as	  fixed	  but	   	  and	   ,	  different	  families	  of	  curves	  can	  be	  generated	  
as	  demonstrated	  in	  Figure	  3.	  Empirically,	  one	  can	  appreciate	  that	  as	   	  increases	  
a	  tumor’s	  curve	  morphology	  generally	  shifts	  from	  a	  continuous	  uptake	  curve	  to	  a	  
plateau	  curve	  to	  a	  washout	  curve.	  	  Likewise,	  as	  ve	  increases	  (i.e.	  as	  the	  cellularity	  of	  
the	  tumor	  decreases),	  the	  curves	  progress	  from	  	  a	  washout	  morphology	  to	  a	  
continuous	  uptake	  morphology.	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Figure	  3	  Simulated	  traces	  of	  concentration	  of	  gadolinium	  generated	  by	  holding	  all	  variables	  defined	  in	  
the	  Tofts	  model	  constant	  and	  varying	  only	  	  (a)	  Ktrans	  and	  then	  (b)	  Ve.	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A	  modification	  of	  the	  standard	  Tofts	  model	  introduces	  an	  additional	  term	  to	  account	  
for	  the	  fraction	  of	  tumor	  that	  is	  occupied	  by	  blood	  vessels.	  	  Contrast	  within	  
microscopic	  intra-­‐tumoral	  blood	  vessels	  technically	  contributes	  to	  the	  concentration	  
of	  contrast	  within	  the	  tumor.	  	  This	  modification,	  called	  the	  extended	  Tofts	  model,	  
adds	  a	  term	  to	  Equation	  (3)	  as	  below	  	  
	   (5)	  
where	   	  is	  the	  fraction	  of	  tumor	  occupied	  by	  blood	  vessels.	  	  
	  
Note	  additionally	  that	  the	  Tofts	  AIF	  represents	  an	  idealization	  of	  the	  concentration	  
of	  contrast	  in	  plasma.	  To	  be	  specific,	  its	  mathematical	  form	  implies	  that	  the	  bolus	  
mixes	  with	  the	  entire	  plasma	  volume	  instantaneously	  at	  the	  same	  moment	  of	  its	  
sudden	  arrival	  at	  the	  modeled	  tissue.	  	  As	  seen	  in	  Figure	  4,	  the	  concentration	  curve	  
begins	  at	  a	  non	  zero	  value	  at	  t=0,	  which	  is	  non-­‐physiologic.	  Instead,	  the	  vascular	  
mixing	  of	  contrast	  is	  a	  complex,	  stochastic	  process	  that	  takes	  a	  finite	  amount	  of	  time.	  	  	  
and	  results	  in	  a	  curve	  much	  different	  from	  its	  ideal	  form	  in	  the	  Tofts	  AIF.	  	  Therefore,	  
for	  this	  thesis,	  we	  utilized	  an	  AIF	  [cp(t)]	  based	  on	  a	  measured	  population	  input	  
function	  from	  the	  literature.	  	  Blood	  plasma	  contrast	  concentration	  curves	  were	  
measured	  in	  multiple	  patients	  and	  averaged	  to	  form	  a	  population	  based	  AIF	  which	  is	  
described	  by	  the	  following	  empirical	  equation	  developed	  by	  by	  Orton	  et.	  al.32	  	  
	  
	   (6)	  
Where,	  




The	  difference	  in	  AIF	  morphology	  between	  Orton’s	  proposed	  AIF	  and	  Tofts	  original	  
formulation	  is	  depicted	  in	  Figure	  4.	  	  It	  is	  important	  to	  note	  that	  while	  the	  above	  
equation	  is	  not	  based	  on	  any	  particular	  physiologic	  model,	  the	  curve	  it	  describes	  
matches	  in-­vivo	  contrast	  concentration	  curves	  measured	  in	  real	  patients.	  33).	  	  	  
Limitations	  of	  using	  a	  population	  based	  input	  function	  are	  revisited	  later	  in	  this	  
manuscript.	  
	  
Figure	  4	  A	  comparison	  of	  the	  AIFs	  of	  both	  the	  Tofts	  model	  (blue)	  and	  that	  of	  Orton	  (red)	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Pharmacokinetic	  Modeling	  of	  DCE-­‐MRI	  and	  Predicting	  Patient	  Response	  to	  Neoadjuvant	  
Therapy	  
	  is	  a	  particularly	  attractive	  target	  for	  the	  investigation	  of	  potential	  prognostic	  
biomarkers	  in	  the	  use	  of	  anti-­‐angiogensis	  drugs	  due	  to	  its	  theoretical	  association	  
with	  the	  vascular	  barrier	  in	  tissue	  as	  well	  as	  the	  ability	  of	  clinicians	  to	  quantify	  it	  
non-­‐invasively	  and	  without	  ionizing	  radiation.	  	  Unfortunately,	  the	  several	  small	  
studies	  conducted	  to	  date	  have	  resulted	  in	  inconsistent	  conclusions	  and	  thus,	  data	  
on	  the	  efficacy	  of	  PK	  modeling	  of	  DCE-­‐MRI	  are	  limited.	  For	  instance:	  Yankeelov	  et.	  al.	  
34	  were	  able	  to	  determine	  a	  statistically	  significant	  shift	  towards	  lower	   	  in	  their	  
analysis	  of	  populations	  of	  voxels	  from	  breast	  lesions	  undergoing	  neoadjuvant	  
therapy	  before	  and	  after	  said	  therapy.	  Importantly,	  while	  there	  appeared	  to	  be	  a	  
shift	  in	   	  due	  to	  the	  use	  of	  neoadjuvant	  therapy,	  responders	  were	  not	  
confidently	  segregated	  from	  non-­‐responders	  and	  the	  prognostic	  value	  of	  this	  
observation	  was	  left	  undetermined.	  Thukral	  et.	  al.35	  observed	  a	  similar	  significant	  
shift	  in	  the	   	  of	  the	  voxel	  populations,	  but,	  when	  compared	  to	  pathology	  data,	  
were	  unable	  to	  show	  any	  difference	  between	  responders	  and	  non-­‐responders.	  
Interestingly,	  this	  stands	  in	  stark	  contrast	  to	  others	  such	  as	  Ah-­‐See	  et.	  al.	  36	  who	  
were	  able	  to	  differentiate	  between	  responders	  and	  non-­‐responders	  by	  utilizing	  
percentage	  change	  in	  the	  median	  value	  of	   	  from	  baseline.	  Compounding	  this	  
confusion	  of	  results	  is	  the	  relatively	  small	  number	  of	  patients	  this	  method	  has	  been	  
applied	  to.	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This	  project	  will	  attempt	  to	  help	  elucidate	  this	  relationship	  by	  focusing	  on	  
prospectively	  analyzing	  a	  group	  of	  breast	  cancer	  patients	  according	  to	  cutoffs	  
established	  by	  several	  investigators.	  In	  2006	  Padhani	  et.	  al.	  37	  noted	  that	  an	  increase,	  
no	  change,	  or	  decrease	  of	  less	  than	  11%	  in	  the	  range	  of	   	  calculated	  over	  a	  
population	  of	  lesion	  voxels	  after	  one	  cycle	  of	  neoadjuvant	  chemotherapy	  had	  an	  
80%	  sensitivity	  and	  76%	  specificity	  in	  distinguishing	  non-­‐responders	  from	  
responders.	  Yu	  et.	  al.38	  noted	  by	  ROC	  analysis	  that	  after	  two	  cycles	  of	  neoadjuvant	  
chemotherapy,	  a	  patient’s	  pathologic	  response	  could	  be	  predicted	  (sensitivity	  81%,	  
specificity	  88%)	  by	  calculating	  the	  median	   	  and	  using	  a	  threshold	  of	  
percentage	  change	  from	  baseline	  of	  -­‐85%.	  	  Ah-­‐See	  et.	  al.	  were	  able	  to	  generate	  a	  
similar	  threshold	  after	  two	  cycles	  neoadjuvant	  chemotherapy	  for	  difference	  in	  
median	   	  of	  -­‐42.1%,	  however	  their	  means	  of	  producing	  this	  criterion	  was	  novel.	  
Before	  initiating	  neoadjuvant	  chemotherapy,	  Ah-­‐See	  et.	  al.	  performed	  two	  baseline	  
imaging	  studies	  that	  could	  be	  used	  to	  generate	  a	  95%	  confidence	  interval	  for	  
repeatability	  of	  the	  difference	  in	  median	  value	  of	   .	  They	  then	  generated	  the	  
cutoff	  used	  in	  their	  criterion	  by	  utilizing	  the	  lower	  bound	  of	  the	  calculated	  
repeatability	  interval	  (i.e.	  any	  lower	  difference	  could	  represent	  a	  statistically	  
significant	  effect).	  With	  this	  in	  mind,	  this	  project	  will	  not	  only	  evaluate	  the	  efficacy	  
of	  each	  of	  the	  mentioned	  criteria	  by	  applying	  them	  prospectively,	  but	  will	  also	  
attempt	  to	  produce	  a	  similar	  repeatability	  interval	  with	  only	  a	  single	  baseline	  
imaging	  study.	  .	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Specified	  Aims	  
This	  study	  aims	  to	  better	  qualify	  the	  relationship	  between	  the	  change	  from	  baseline	  
of	  the	  DCE-­‐MRI	  measured	  pharmacokinetic	  parameter	   ,	  and	  a	  patient’s	  
response	  to	  neoadjuvant	  chemotherapy	  with	  an	  anti-­‐angiogenic	  agent	  for	  breast	  
cancer.	  To	  accomplish	  this	  goal,	  this	  project	  will	  prospectively	  apply	  the	  cut-­‐offs	  of	  
change	  in	   	  reported	  by	  Padhani	  et.	  al.,	  Yu	  et.	  al.,	  and	  Ah-­‐See	  et.	  al.	  to	  patients	  
undergoing	  neoadjuvant	  chemotherapy	  for	  breast	  cancer.	  Additionally,	  it	  will	  
evaluate	  the	  efficacy	  of	  using	  a	  repeatability	  interval	  cutoff	  as	  described	  by	  Ah-­‐See	  
et.	  al.,	  but	  generated	  with	  only	  a	  single	  baseline	  imaging	  study.	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Methods	  
This	  thesis	  project	  was	  conducted	  utilizing	  data	  acquired	  as	  part	  of	  an	  ongoing	  
collaboration	  between	  the	  Yale	  University	  School	  of	  Medicine	  (YSM)	  and	  the	  Brown	  
University	  Oncology	  Group	  (BrUOG)	  to	  evaluate	  the	  effectiveness	  of	  neoadjuvant	  
therapy	  in	  the	  treatment	  of	  breast	  cancer.	  As	  such,	  a	  full	  description	  of	  the	  methods	  
utilized	  in	  this	  study	  must	  necessarily	  include	  both	  the	  procedures	  specifically	  
derived	  to	  meet	  the	  specified	  aim	  as	  well	  as	  those	  developed	  for	  the	  larger	  
collaborative	  effort,	  and	  generative	  of	  the	  data	  pertinent	  to	  this	  study.	  To	  make	  this	  
distinction	  explicit,	  note	  that	  the	  ensuing	  subsections	  describing	  patient	  
recruitment,	  treatment,	  and	  data	  acquisition	  are	  the	  product	  of	  the	  protocol	  for	  the	  
larger	  collaboration	  and	  are	  were	  not	  developed	  as	  part	  of	  this	  thesis.	  	  Subsections	  
outlining	  the	  methods	  for	  data	  and	  statistical	  analysis	  were	  specifically	  developed	  
for	  this	  thesis.	  
	  
Patient	  Recruitment	  and	  Treatment	  
Patients	  eligible	  for	  the	  larger	  collaborative	  effort	  between	  YSM	  and	  BrUOG	  were	  
patients	  with	  biopsy	  proven	  breast	  cancers	  larger	  than	  2	  cm	  in	  size.	  	  The	  
collaborative	  effort	  attempted	  to	  recruit	  60	  patients	  with	  HER2	  negative	  breast	  
cancers	  and	  60	  patients	  with	  HER2	  positive	  breast	  cancers.	  Once	  admitted,	  patients	  
were	  randomized	  to	  one	  of	  two	  study	  arms:	  one	  providing	  traditional,	  small-­‐
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molecule	  neoadjuvant	  chemotherapy	  with	  paclitaxel	  and	  carboplatin,	  the	  other	  
utilizing	  anti-­‐angiogenesis	  agents	  (bevacizumab	  for	  HER2	  negative	  cancers	  and	  
trastuzumab	  for	  HER2	  positive	  cancers).	  Before	  initiating	  neoadjuvant	  therapy,	  a	  
baseline	  breast	  MR	  was	  obtained.	  This	  initial	  imaging	  was	  repeated	  at	  +1	  week	  after	  
initiation	  of	  neoadjuvant	  therapy	  and	  again	  at	  no	  less	  than	  +15	  weeks	  from	  therapy	  
initiation	  and	  prior	  to	  planned	  surgical	  procedure	  for	  removal	  of	  the	  lesion.	  Surgical	  
specimens	  were	  collected	  at	  removal	  for	  assessment	  of	  pathological	  response.	  This	  
response	  was	  classified	  into	  one	  of	  three	  categories:	  complete	  response,	  partial	  
response,	  and	  poor	  response.	  
	  
To	  be	  included	  in	  the	  analysis	  conducted	  for	  this	  thesis	  project,	  patients	  must	  have	  
been	  randomized	  to	  the	  anti-­‐angiogenesis	  	  arm	  of	  the	  collaborative	  study	  and	  have	  
been	  recruited	  early	  enough	  that	  the	  previously	  described	  baseline	  and	  +1	  week	  
imaging	  (hereafter	  referred	  to	  as	  imaging	  conducted	  at	  time	  points	  one	  and	  two,	  
respectively)	  could	  be	  obtained,	  and	  additionally,	  have	  remained	  in	  the	  study	  long	  
enough	  that	  definitive	  pathological	  assessment	  had	  been	  conducted	  and	  could	  be	  
included	  in	  analysis.	  Furthermore,	  each	  imaging	  study	  conducted	  at	  time	  points	  one	  
and	  two	  must	  have	  had	  sufficient	  temporal	  resolution	  to	  be	  compatible	  with	  PK	  
analysis.	  A	  brief	  description	  and	  comparison	  of	  the	  two	  methods	  for	  imaging	  utilized	  
in	  the	  collaborative	  study	  ensues.	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Data	  Acquisition	  
All	  DCE-­‐MRI	  studies	  acquired	  as	  part	  of	  the	  collaborative	  effort	  were	  conducted	  
according	  to	  one	  of	  two	  methods.	  The	  most	  common	  sequence	  (acquired	  at	  Brown	  
and	  at	  out-­‐patient	  imaging	  centers)	  was	  designed	  to	  produce	  studies	  amenable	  to	  
analysis	  by	  the	  previously	  mentioned	  SER	  method.	  As	  such,	  three	  volumes	  were	  
acquired:	  one	  prior	  to	  administration	  of	  gadolinium,	  one	  “peak”	  volume	  taken	  at	  the	  
presumed	  arrival	  of	  bolus	  (typically	  75	  seconds	  post	  gadolinium	  administration),	  
and	  one	  volume	  post-­‐arterial	  phase	  of	  contrast	  (typically	  at	  six	  minutes	  post-­‐
gadolinium).	  Images	  were	  obtained	  using	  a	  3	  dimensional	  spoiled	  gradient	  echo	  T1	  
weighted	  fat	  suppressed	  sequence.	  The	  resulting	  studies	  were	  of	  high	  spatial	  
resolution	  (2mm	  x	  1	  mm	  x	  	  1mm)	  and	  signal	  to	  noise,	  but	  	  with	  only	  three	  data	  
points	  over	  six	  minutes	  –	  of	  insufficient	  temporal	  resolution	  to	  curve-­‐fit	  the	  
concentration	  of	  gadolinium.	  	  	  
	  
The	  protocol	  utilized	  to	  achieve	  high	  temporal	  resolution	  utilized	  an	  innovative	  k-­‐
space	  sharing	  technique	  (TWIST,	  Siemens	  Medical	  Systems)	  where	  the	  central	  
portions	  of	  k-­‐space	  are	  oversampled	  at	  high	  temporal	  resolution	  and	  combined	  with	  
peripheral	  k-­‐space	  data	  acquired	  at	  different	  times.	  	  Since	  contrast	  information	  is	  
located	  in	  the	  central	  k-­‐space	  regions	  overall	  tumor	  signal	  intensities	  are	  updated	  at	  
high	  temporal	  resolution.	  	  Since	  edge	  data	  is	  contained	  in	  the	  periphery	  of	  k-­‐space,	  
which	  is	  relatively	  under-­‐sampled	  with	  this	  technique,	  	  tumor	  margins	  become	  
slightly	  less	  distinct.	  	  The	  details	  of	  this	  technique	  are	  beyond	  the	  scope	  of	  this	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thesis.	  	  	  The	  imaging	  protocol	  was	  determined	  by	  the	  radiologist	  on	  the	  study	  and	  
was	  set	  prior	  to	  the	  initiation	  of	  this	  thesis	  project.	  
	  
Images	  obtained	  on	  patients	  recruited	  at	  Yale	  were	  obtained	  using	  this	  technique	  
resulting	  in	  a	  high	  temporal	  resolution	  (4-­‐7	  seconds	  per	  volume)	  	  and	  relatively	  low	  
spatial	  resolution	  (5mm	  x	  1mm	  x	  1	  mm)	  dynamic	  series	  using	  the	  following	  
parameters:	  	  TR:	  3.5	  ms,	  TE:	  1.5	  ms,	  field	  of	  view:	  350	  mm,	  and	  image	  matrix	  320	  x	  
320.	  	  For	  the	  purposes	  of	  T1	  mapping	  (as	  described	  subsequently)	  a	  reference	  
image	  was	  acquired	  using	  a	  flip	  angle	  of	  3	  or	  5	  degrees.	  	  Subsequently,	  repeated	  
measures	  were	  acquired	  for	  5	  minutes	  using	  a	  flip	  angle	  of	  25	  degrees.	  	  0.1	  mmol	  /	  
kg	  of	  Magnevist	  IV	  contrast	  was	  injected	  at	  2	  cc	  /sec	  through	  an	  upper	  extremity	  
peripheral	  IV	  after	  the	  4th	  acquired	  volume.	  
	  
	  
Of	  30	  patients	  recruited	  a	  the	  Yale	  site,	  only	  11	  were	  enrolled	  before	  their	  initial	  
MRI	  and	  underwent	  high	  temporal	  resolution	  DCE-­‐MRI	  before	  and	  after	  initial	  
exposure	  to	  chemotherapy.	  	  Of	  these	  11	  patients,	  only	  7	  underwent	  successful	  DCE-­‐
MRI	  at	  both	  time	  points.	  	  This	  results	  in	  a	  study	  population	  of	  only	  7	  patients.	  
	  
Data	  Post-­‐Processing	  
Data	  gathered	  as	  described	  above	  were	  analyzed	  utilizing	  a	  specially	  developed	  
software	  platform,	  DCLab,	  written	  by	  the	  author	  in	  MATLAB.	  This	  analysis	  
constituted	  the	  central	  portion	  of	  this	  thesis.	  	  One	  of	  the	  primary	  goals	  in	  developing	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this	  software	  was	  to	  allow	  for	  the	  exploration	  and	  development	  of	  novel	  and	  
literature	  proposed	  pharmacokinetic	  models	  in	  disparate	  organ	  systems.	  As	  such,	  
DCLab	  was	  written	  according	  to	  object-­‐oriented	  principles	  to	  afford	  modularity	  and	  
easy	  extensibility.	  	  A	  brief	  explanation	  of	  the	  class	  hierarchy	  used	  for	  the	  
implementation	  of	  pharmacokinetic	  models	  is	  outlined	  in	  Appendix	  A.	  	  Note	  that	  the	  
flexibility	  afforded	  authors	  coding	  for	  DCLab	  is	  derived	  from	  the	  abstraction	  and	  
compartmentalization	  of	  the	  various	  steps	  in	  its	  analytical	  workflow.	  A	  brief	  
overview	  of	  that	  process	  follows:	  	  
	  
1. All	  images	  from	  both	  dynamic	  and	  reference	  series	  are	  loaded	  into	  working	  
memory	  and	  subsequently	  organized	  into	  discrete,	  time-­‐sorted	  collections	  of	  
volumes	  
2. The	  spatial	  location	  of	  a	  lesion	  is	  identified	  in	  the	  dynamic	  series	  and	  the	  
perimeter	  of	  an	  encompassing	  volume	  of	  interest	  is	  drawn	  at	  the	  volume’s	  
intersection	  with	  the	  acquired	  slices,	  thus	  defining	  a	  volume	  of	  interest	  (VOI)	  
3. An	  initial	  (pre-­‐contrast)	  T1	  value	  for	  each	  voxel	  of	  the	  VOI	  is	  calculated	  and	  
stored.	  	  	  
4. Using	  the	  baseline	  T1	  values	  calculated	  in	  step	  3,	  the	  concentration	  of	  
contrast	  at	  each	  voxel	  of	  the	  VOI	  over	  the	  span	  of	  the	  dynamic	  series	  is	  
calculated	  
5. Each	  time	  vs	  contrast	  curve	  generated	  by	  step	  4	  is	  used	  to	  fit	  a	  user-­‐selected	  
pharmacokinetic	  model	  (in	  the	  case	  of	  this	  project,	  the	  extended	  Tofts	  model	  
with	  the	  Orton	  AIF).	  The	  results	  of	  which	  are	  presented	  to	  the	  user	  
	   27	  
	  
The	  ensuing	  discussion	  will	  describe	  the	  implementation	  of	  pertinent,	  non-­‐trivial	  
aspects	  of	  DCLab’s	  analytical	  workflow.	  
	  
Determining	  Tissue	  Gadolinium	  Concentration	  
	  
Generally	  in	  DCE-­‐MRI,	  converting	  from	  measured	  signal	  intensity	  to	  tissue	  
gadolinium	  concentration	  is	  achieved	  via	  one	  of	  two	  separate	  means.	  One	  is	  the	  
physical	  construction	  and	  use	  of	  an	  apparatus	  that	  houses	  multiple	  phantoms	  of	  
known	  T1	  (representing	  discrete	  intervals	  of	  the	  full	  range	  of	  T1	  expected	  of	  
gadolinium)	  that	  can	  be	  placed	  comfortably	  alongside	  the	  patient39.	  This	  method	  
ensures	  both	  patient	  and	  materials	  of	  known	  T1	  can	  be	  scanned	  at	  the	  same	  time,	  
therefore	  allowing	  T1	  to	  be	  derived	  by	  interpolating	  the	  measured	  signal	  against	  a	  
reference	  curve.	  	  However,	  this	  is	  impractical	  in	  the	  setting	  of	  a	  clinical	  trial	  
performed	  in	  a	  clinical	  environment.	  Additionally,	  there	  is	  no	  room	  for	  such	  a	  
phantom	  in	  the	  breast	  coils	  used	  at	  our	  institution.	  
	  
The	  second	  method	  involves	  establishing	  a	  baseline	  T1	  map	  of	  each	  voxel	  in	  the	  
volume	  of	  interest	  (VOI).	  	  	  Measured	  signal	  intensity	  within	  a	  VOI	  	  is	  determined	  by	  
the	  T1	  properties	  of	  the	  tissues	  within	  that	  VOI.	  	  As	  discussed	  in	  the	  following	  
section,	  the	  relationship	  between	  T1	  and	  measured	  signal	  intensity	  can	  be	  
determined	  if	  the	  parameters	  of	  the	  imaging	  sequence	  are	  known.	  	  Gadolinium	  
concentrations	  within	  a	  given	  tissue	  can	  be	  determined	  by	  first	  converting	  changes	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in	  tissue	  signal	  intensity	  to	  changes	  in	  tissue	  T1.	  	  Changes	  in	  tissue	  T1	  are	  related	  to	  
changes	  in	  gadolinium	  concentration	  according	  to	  the	  equation	  	  
delta(Concentration)	  =	  1/Relaxivity(	  delta1/T1)	  .	  	  Therefore,	  by	  measuring	  how	  T1	  




Calculating	  a	  Baseline	  T1	  Map:	  
	  
According	  to	  the	  Bloch	  equations,	  signal	   	  derived	  from	  a	  gradient	  recalled	  echo	  
(GRE)	  sequence	  with	  flip	  angle	   	  can	  is	  represented	  mathematically	  as	  	  	  
	  
	   (7)	  
where	   ,	   	  and	   	  represents	  the	  contribution	  to	  signal	  from	  
machine	  gain,	  proton	  density,	  and	  T2*.	  	  As	  first	  observed	  by	  Mansfield	  and	  Morris	  40	  
when	   	  equation	  (7)	  reduces	  to	  
	  
	   (8)	  
	  Rearranging	  equation	  (8)	  produces	  
	  
	   (9)	  
The	  key	  observation	  that	  enables	  calculation	  of	  T1	  is	  that	  equation	  (9)	  has	  the	  form	  
	  where	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Thus,	  with	  two	  measured	  signal	  intensities,	   ,	  at	  the	  same	  point	  spatially	  but	  at	  
differentflip	  angles	   ,	  an	  initial	  T1	  map	  can	  be	  calculated	  over	  the	  VOI	  by	  solving	  
for	  m	  at	  each	  voxel	  (E1	  contains	  the	  constants	  TR	  and	  T1.	  	  TR	  is	  known	  and	  T1	  can	  
then	  be	  determined).	  This	  relationship	  has	  been	  found	  to	  be	  experimentally	  valid	  
over	  the	  expected	  physiologic	  range	  of	  gadolinium	  provided	  that	  sequence	  
parameters	  are	  carefully	  chosen41.	  
	  
One	  important	  consideration	  to	  facilitating	  an	  accurate	  estimation	  of	  local	  T1	  is	  to	  
correctly	  select	  signal	  to	  be	  utilized	  in	  the	  preceding	  calculations.	  	  	  DCLab	  
accomplishes	  this	  by	  first	  averaging	  the	  signal	  obtained	  from	  each	  voxel	  in	  the	  VOI	  
over	  all	  volumes	  in	  the	  reference	  series	  and	  doing	  the	  same	  for	  all	  volumes	  in	  the	  
dynamic	  series	  that	  are	  captured	  before	  the	  local	  arrival	  of	  the	  contrast	  bolus.	  Note	  
that	  this	  necessarily	  requires	  identifying	  the	  time	  point	  at	  which	  the	  bolus	  arrives	  
before	  any	  attempts	  at	  deriving	  T1.	  This	  is	  accomplished	  by	  expanding	  the	  free	  
parameters	  of	  the	  extended	  Tofts	  model	  to	  fit	  an	  additional	  parameter	  representing	  
the	  arrival	  of	  the	  bolus,	   ,	  as	  follows:	  
	  
	   (10)	  
It	  should	  be	  noted,	  however,	  that	  the	  initial	  T1	  map	  must	  be	  estimated	  before	  
calculation	  of	  gadolinium	  contrast	  can	  be	  accomplished.	  Because	  the	  model	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presented	  in	  equation	  (10)	  is	  designed	  for	  output	  data	  in	  units	  of	  concentration	  of	  
contrast,	  an	  approximation	  must	  be	  made	  at	  this	  stage	  to	  ensure	  that	  any 	  
discovered	  by	  matching	  an	  objective	  function	  based	  on	  equation	  (10)	  to	  signal	  of	  
arbitrary	  units	  is	  accurate.	  DCLab	  makes	  use	  of	  a	  relationship	  observed	  by	  Walker-­‐
Samuel	  et.	  al.42	  to	  accomplish	  this.	  This	  relationship	  holds	  that,	  as	  a	  reasonable	  
approximation,	  the	  concentration	  of	  gadolinium	  in	  tissue	  varies	  linearly	  over	  its	  
physiologic	  range	  with	  the	  following	  ratio	  of	  signals	  
	   	   	  
Where	   	  represents	  the	  signal	  from	  the	  dynamic	  series,	  and	   	  a	  separate	  series	  
with	  a	  flip	  angle	   	  such	  that	   .	  In	  the	  case	  of	  the	  index	  imaging	  study,	  this	  
criteria	  is	  met	  by	  the	  reference	  series	  (flip	  of	  3-­‐5	  degrees).	  DCLab	  thus	  calculates	  the	  
average	  signal	  ratio	  over	  the	  VOI	  for	  each	  time	  point	  in	  the	  dynamic	  series,	  scales	  
the	  resulting	  set	  to	  the	  physiologic	  range	  of	  gadolinium	  contrast	  and	  fits	  to	  that	  set,	  
the	  model	  represented	  by	  equation	  (10).	  In	  so	  doing,	   	  can	  be	  calculated	  and	  the	  
dynamic	  series	  segmented	  into	  signal	  obtained	  before	  and	  after	  bolus	  arrival.	  
	  
Calculating	  the	  Contrast	  of	  Gadolinium	  	  
Once	  the	  initial	  T1	  map	  has	  been	  calculated,	  the	  remaining	  unknowns	  in	  equation	  
(8)	  can	  be	  solved	  for	  at	  time	  points	  before	  the	  arrival	  of	  contrast.	  In	  particular,	   	  
can	  be	  calculated	  as	  follows:	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Where and 	  are	  the	  signal	  and	  flip	  angle,	  respectively,	  of	  the	  dynamic	  series.	  
Because 	  is	  not	  expected	  to	  vary	  with	  the	  arrival	  of	  gadolinium,	  the	  T1	  for	  all	  
voxels	  in	  the	  VOI	  and	  at	  each	  time	  point	  in	  the	  dynamic	  series	  can	  be	  calculated	  by	  




Using	  this	  equation,	  the	  T1	  at	  each	  time	  point	  for	  all	  voxels	  can	  be	  calculated,	  and	  
the	  concentration	  of	  contrast	  is	  
	  
	   	  
Where	   	  is	  the	  unit	  longitudinal	  relaxivity	  of	  Magnevist	  in	  plasma.	  
	  
Fitting	  the	  Extended	  Tofts	  Model	  
The	  mechanics	  of	  matching	  the	  extended	  Tofts	  model	  defined	  in	  equation	  (5)	  to	  the	  
observational	  data	  requires	  special	  explanation.	  DCLab	  utilizes	  the	  Levenberg-­‐
Marquardt	  non-­‐linear	  least	  squares	  curve-­‐fitting	  algorithm	  as	  it	  has	  been	  shown	  to	  
generate	  superior	  performance	  with	  regard	  to	  percentage	  of	  data	  accurately	  fit	  than	  
other	  employed	  methods43.	  The	  Levenberg-­‐Marquardt	  algorithm	  searches	  through	  
an	  N-­‐d	  problem	  space,	  where	  N	  is	  the	  number	  of	  parameters	  to	  be	  fit,	  by	  iteratively	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perturbing	  each	  of	  the	  target	  parameters	  so	  as	  to	  minimize	  the	  sum-­‐squared	  error	  
of	  an	  objective	  function	  (in	  this	  case,	  the	  extended	  Tofts	  model)	  to	  provided	  
observational	  data.	  Like	  all	  optimization	  algorithms	  of	  this	  sort,	  the	  performance	  of	  
Levenberg-­‐Marquardt	  is	  seed-­‐dependent:	  	  its	  ultimate	  output	  may	  represent	  a	  local,	  
rather	  than	  global,	  minimum	  in	  the	  problem	  space.	  	  
	  
DCLab	  attempts	  to	  reduce	  this	  potential	  for	  error	  by	  allowing	  a	  user	  to	  seed	  
Levenberg-­‐Marquardt	  with	  an	  arbitrary	  number	  of	  “initial	  guesses”	  and	  returning	  
the	  parameters	  that	  resulted	  in	  the	  single	  “best.”	  Note	  that,	  in	  this	  study,	  the	  number	  
of	  guesses	  chosen	  represents	  a	  compromise	  between	  compute	  time	  and	  coverage	  of	  
the	  problem	  space.	  To	  be	  specific,	  the	  problem	  space	  spanned	  by	  physiologic	   	  
and	   	  (note	  that	   	  was	  not	  included	  as	  its	  physiologic	  range	  is	  much	  smaller	  than	  
either	  of	  the	  other	  two	  utilized	  parameters)	  was	  divided	  into	  4	  equally	  sized	  
segments,	  the	  centers	  of	  which	  were	  each	  included	  as	  an	  initial	  seed.	  In	  addition,	  the	  
center	  of	  the	  entire	  previously-­‐described	  problem	  space	  and	  the	  parameters	  that	  
generated	  the	  last	  successful	  fit	  were	  also	  included.	  Using	  this	  set	  of	  seeds	  the	  
Levenberg-­‐Marquardt	  algorithm	  was	  run	  for	  each	  time	  vs.	  concentration	  trace	  at	  
each	  voxel	  in	  the	  VOI.	  A	  “successful	  fit”	  was	  defined	  as	  algorithmic	  output	  that	  
yielded	  parameters	  falling	  within	  their	  known	  physiologic	  range	  (for	  instance	   	  
and	   	  are	  fractions	  ranging	  from	  0	  to	  1,	  an	  algorithmic	  output	  yielding	  a	  value	  for	  
either	  above	  1	  or	  beneath	  0	  was	  rejected).	  If	  more	  than	  one	  seed	  was	  successfully	  fit,	  
the	  set	  of	  output	  parameters	  that	  yielded	  the	  lowest	  sum-­‐squared	  error	  was	  chosen	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as	  the	  returned	  fit	  for	  each	  voxel.	  If	  no	  seed	  was	  successfully	  fit,	  the	  voxel	  was	  
removed	  from	  further	  analysis.	  
	  
Fixed	  PK	  Parameter	  Valuation	  
As	  noted	  previously,	  DCLab	  utilizes	  a	  population-­‐based	  AIF.	  The	  fixed	  parameters	  
noted	  in	  Equation	  (6)	  are	  provided	  by	  Orton32	  and	  were	  produced	  via	  modeling	  on	  
simulated	  data44.	  	  Additionally,	  the	  unit	  longitudinal	  relaxivity	  of	  Magnevist	  in	  
plasma	  was	  obtained	  from	  in-­‐vivo	  estimations	  reported	  by	  Pintaske	  et.	  al.	  45.	  	  
Statistical	  Analysis	  
All	  patient	  studies	  processed	  by	  DCLab	  had	  the	  following	  measurements	  recorded:	  
the	  median	  and	  range	  of	   	  over	  all	  voxels	  in	  the	  VOI	  and	  a	  histogram	  of	  the	   	  
calculated	  at	  each	  voxel	  in	  the	  VOI.	  A	  non-­‐parametric	  Mann-­‐Whitney	  U	  test	  was	  
utilized	  to	  compare	  the	  percentage	  change	  in	  median	   	  from	  time	  point	  one	  to	  
two	  between	  responders	  and	  non-­‐responders	  by	  pathology.	  Percentage	  change	  in	  
median	   	  was	  compared	  to	  cutoffs	  of	  an	  increase,	  no	  change,	  or	  less	  than	  85%	  
(in	  the	  case	  of	  the	  Yu	  criterion)	  and	  42%	  (in	  the	  case	  of	  the	  Ah-­‐See	  criterion)	  
decrease	  in	   	  to	  classify	  each	  patient	  meeting	  the	  criterion	  as	  a	  “predicted	  non-­‐
responder”	  otherwise	  a	  “predicted	  responder”.	  Similarly,	  a	  percentage	  change	  of	  the	  
range	  of	   	  that	  showed	  an	  increase,	  no	  change,	  or	  less	  than	  11%	  decrease	  was	  
classified	  as	  a	  “predicted	  non-­‐responder”	  and	  otherwise	  a	  “predicted	  responder.”	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This	  thesis	  additionally	  calculated	  a	  repeatability	  range	  for	  the	  difference	  in	  median
,	  the	  lower	  bound	  of	  which	  was	  utilized	  as	  an	  additional	  criterion	  for	  
predicting	  pathologic	  response.	  Because	  this	  thesis	  had	  imaging	  from	  only	  a	  single	  
study	  before	  the	  administration	  of	  neoadjuvant	  chemotherapy,	  the	  repeatability	  
range	  could	  not	  be	  calculated	  by	  strictly	  repeating	  Ah-­‐See’s	  method.	  Instead,	  it	  was	  
found	  by	  first	  randomly	  segmenting	  the	  baseline	  lesion	  voxels	  into	  two	  distinct	  
populations	  for	  each	  patient.	  Using	  these	  two	  populations	  the	  difference	  median
	  could	  be	  calculated	  and,	  according	  to	  Ah-­‐See,	  the	  repeatability	  range	  is	  	  
	  
Where	  n	  is	  the	  number	  of	  studies	  and	  d	  is	  the	  percentage	  change	  in	  median	   .	  
Thus,	  if	  the	  percentage	  change	  showed	  an	  increase,	  no	  change,	  or	  decrease	  less	  than	  
that	  provided	  by	  the	  lower	  bound	  of	  the	  repeatability	  range	  it	  was	  classified	  a	  
“predicted	  non-­‐responder,”	  otherwise	  a	  “predicted	  responder.”	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Results	  
To	  date,	  106	  women	  have	  been	  admitted	  to	  the	  anti-­‐angiogenic	  arm	  of	  the	  
YSM/BrUOG	  trial.	  30	  of	  this	  cohort	  have	  undergone	  the	  high-­‐temporal	  DCE-­‐MRI.	  	  
However,	  since	  most	  of	  the	  patients	  were	  enrolled	  after	  an	  initial	  clinical	  breast	  MRI	  
detected	  their	  breast	  cancer,	  only	  	  11	  patients	  had	  high	  temporal	  resolution	  DCR-­‐
MRI	  performed	  at	  baseline.	  Of	  these,	  four	  had	  to	  be	  dropped	  from	  analysis	  due	  to	  
incorrectly	  acquired	  reference	  series	  (n=2),	  unrecorded	  reference	  series	  (n=1),	  or	  a	  
dynamic	  series	  with	  image	  acquisition	  begun	  post-­‐bolus	  arrival	  (n=1).	  
	  
On	  analysis	  of	  the	  surgical	  specimens	  acquired	  after	  completion	  of	  neoadjuvant	  
chemotherapy,	  two	  women	  were	  noted	  to	  have	  lesions	  that	  responded	  by	  pathology	  
and	  five	  were	  classified	  non-­‐responders.	  
	  
The	  calculation	  of	   over	  all	  voxels	  of	  each	  included	  patient’s	  lesion	  can	  be	  
described	  via	  the	  statistical	  descriptors	  reported	  in	  Table	  (1)	  and	  representative	  
histograms	  detailing	  the	  transformation	  of	   	  from	  time	  point	  one	  to	  two	  are	  
diagrammed	  in	  Figure	  (5)	  for	  representative	  patients.	  In	  addition,	  the	  average	  
concentration	  of	  contrast	  over	  lesions	  taken	  from	  time	  points	  one	  and	  two	  –	  as	  well	  


















1	   63%	   0.107±0.06	   0.096	   0.717	  1	  
2	   78%	   0.212±0.13	   0.174	   0.867	  
Negative	  
1	   60%	   0.516±0.24	   0.514	   1.678	  2	   2	   55%	   0.470±0.20	   0.441	   0.981	   Negative	  
1	   73%	   0.500±0.20	   0.500	   1.408	  3	   2	   40%	   0.421±0.22	   0.377	   1.414	   Negative	  
1	   96%	   0.106±0.05	   0.062	   0.913	  4	   2	   90%	   0.229±0.15	   0.204	   0.917	   Negative	  
1	   79%	   0.149±0.10	   0.137	   0.556	  5	   2	   62%	   0.202±0.11	   0.180	   0.647	   Negative	  
1	   84%	   0.358±0.19	   0.315	   1.168	  6	   2	   82%	   0.096±0.03	   0.082	   0.459	   Positive	  
1	   73%	   0.590±0.24	   0.606	   0.999	  7	   2	   79%	   0.474±0.26	   0.432	   1.015	   Positive	  
Table	  1	  For	  both	  time	  points	  collected	  for	  each	  patient,	  the	  percentage	  of	  lesion	  voxels	  fit	  via	  PK	  
modeling;	  the	  pathological	  response	  of	  the	  lesion	  to	  antiangiogenic	  therapy;	  and	  statistical	  descriptors	  
of	  the	  Ktrans	  calculated	  for	  each	  voxel	  in	  the	  target	  lesion.	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Figure	  5	  Histograms	  of	  the	  calculated	  per-­voxel	  Ktrans	  over	  a	  lesion’s	  VOI.	  Note	  that	  patient	  1	  is	  a	  non-­
responder	  by	  pathology;	  her	  Ktrans	  histograms	  are	  given	  at	  time	  points	  (a)1	  and	  (b)	  2.	  Patient	  6	  is	  a	  
responder	  by	  pathology;	  her	  Ktrans	  histograms	  are	  given	  at	  time	  points	  (a)	  1	  and	  (b)	  2.	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Figure	  6.	  Traces	  of	  the	  average	  measured	  concentration	  of	  contrast	  over	  a	  lesion’s	  VOI	  as	  well	  as	  the	  
trace	  of	  the	  best-­fit	  PK	  model.	  Note	  that	  patient	  1	  is	  a	  non-­responder	  by	  pathology.	  (a)	  Gives	  her	  average	  
trace	  and	  fit	  at	  time	  point	  1	  (modeled	  Ktrans=0.108,	  Ve=0.325),	  and	  (b)	  her	  average	  trace	  and	  fit	  at	  time	  
point	  2	  (modeled	  Ktrans=0.1684,	  Ve=0.500).	  Patient	  6	  is	  a	  responder	  by	  pathology.	  (a)	  Gives	  her	  average	  
trace	  and	  fit	  at	  time	  point	  1	  (modeled	  Ktrans=0.295,	  Ve=0.694),	  and	  (b)	  her	  average	  trace	  and	  fit	  at	  time	  
point	  2	  (modeled	  Ktrans=0.135,	  Ve=0.565).	  
By	  performing	  the	  non-­‐parametric	  Mann-­‐Whitney	  U	  test	  for	  significance	  on	  the	  
difference	  between	  median	   	  values	  from	  time	  point	  one	  to	  two	  and	  using	  an	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,	  the	  mean	  difference	  between	  the	  responders	  and	  non-­‐responders	  cannot	  
be	  determined	  to	  be	  statistically	  significant	  at	  this	  level	  of	  power	  (p=0.0952).	  
	  
After	  scaling	  the	  pertinent	  values	  in	  Table	  (1)	  against	  their	  respective	  initial	  levels	  at	  
time	  point	  one,	  the	  Padhani,	  Yu,	  and	  Ah-­‐See	  criteria	  for	  identifying	  pathological	  




By	  running	  twenty-­‐five	  simulations	  where	  each	  lesion	  at	  time	  point	  one	  was	  
segmented	  into	  two	  distinct	  populations	  randomly	  and	  their	  difference	  in	  median	  
	  was	  utilized	  to	  calculate	  a	  repeatability	  interval,	  the	  average	  lower	  bound	  was	  
-­‐34.7	  ±	  3.76%.	  	  The	  result	  of	  using	  this	  criterion	  to	  predict	  pathological	  response	  by	  
individual	  patients	  is	  provided	  in	  Table	  (2).	  
	  
















1	   +82%	   +21%	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	  
2	   -­‐14%	   -­‐42%	   +	   -­‐	   -­‐	   -­‐	   -­‐	  
3	   -­‐24%	   0%	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	  
4	   +116%	   0%	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	  
5	   +36%	   +16%	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	  
6	   -­‐73%	   -­‐61%	   +	   -­‐	   +	   +	   +	  
7	   -­‐29%	   +2%	   -­‐	   -­‐	   -­‐	   -­‐	   +	  
Table	  2	  Predicted	  Response	  to	  Therapy	  According	  to	  Literature	  and	  Proposed	  Criteria.	  For	  each	  patient	  
in	  the	  study	  (ID),	  the	  percentage	  change	  between	  time	  points	  one	  and	  two	  of	  the	  median	  and	  range	  of	  
Ktrans	  are	  provided.	  Utilizing	  these	  values,	  the	  results	  of	  applying	  the	  Padhani,	  Yu,	  Ah-­See,	  and	  the	  
proposed	  criteria	  are	  shown	  (note	  that	  “+”	  is	  equivalent	  to	  “predicted	  responder”	  and	  “-­“	  is	  equivalent	  to	  
“predicted	  non-­responder”)	  as	  well	  as	  the	  final	  pathological	  response	  (PR).	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Discussion	  
Although	  the	  limited	  amount	  of	  data	  associated	  with	  this	  project	  necessarily	  limits	  
the	  conclusions	  one	  may	  draw,	  there	  remain	  several	  observations	  that	  necessitate	  
consideration.	  This	  discussion	  will	  focus	  on	  trends	  and	  findings	  either	  in	  agreement	  
with	  or	  opposition	  to	  previously	  published	  work.	  
	  
Many	  of	  the	  preceding	  experiments	  (excepting	  Padhani)	  that	  attempt	  to	  derive	  a	  
means	  of	  predicting	  pathological	  response	  to	  neoadjuvant	  therapy	  by	  way	  of	  change	  
over	  a	  population	  of	   	  remark	  that,	  retrospectively,	  the	  difference	  between	  
median	   	  from	  some	  point	  during	  therapy	  to	  baseline	  is	  significantly	  different	  if	  
a	  patient	  is	  determined	  to	  have	  responded	  to	  therapy	  than	  if	  she	  hasn’t.	  This	  finding	  
could	  not	  be	  reproduced	  in	  this	  thesis.	  The	  reason	  here	  is	  unsatisfying:	  this	  study	  is	  
simply	  too	  underpowered.	  Note	  that	  the	  statistical	  test	  for	  determining	  a	  difference	  
between	  the	  means	  of	  two	  potentially	  different	  datasets,	  the	  Mann-­‐Whitney	  U	  test,	  
cannot	  generate	  a	  p	  value	  less	  than	  that	  noted	  above	  (p=0.0952)	  for	  any	  member	  
valuation	  of	  sets	  of	  cardinality	  2	  and	  5.	  The	  responders	  in	  this	  study	  have	  greater	  
negative	  difference	  in	  median	   	  than	  non-­‐responders:	  the	  trend	  is	  in	  the	  correct	  
direction.	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While	  the	  absolute	  values	  of	   	  reported	  in	  this	  thesis	  appear	  to	  fall	  within	  the	  
range	  of	  that	  reported	  elsewhere,	  one	  glaring	  difference	  deserves	  consideration.	  
Specifically,	  previous	  reports	  that	  utilize	  curve	  fitting	  have	  yielded	  higher	  
percentages	  of	  voxels	  fit	  than	  here.	  One	  important	  point,	  when	  considering	  why	  this	  
may	  be,	  is	  to	  focus	  on	  the	  centrality	  of	  the	  shape	  of	  the	  population-­‐derived	  AIF	  to	  the	  
morphologic	  range	  of	  concentration	  curves	  that	  can	  be	  fit	  with	  physiologically	  
ranged	  free	  parameters.	  
	  
A	  population-­‐derived	  AIF	  is	  static;	  it	  cannot	  account	  for	  variation	  in	  the	  speed	  at	  
which	  the	  bolus	  was	  pushed,	  the	  patient’s	  cardiac	  output,	  nor	  the	  process	  of	  contrast	  
mixing	  (among	  other	  factors).	  Consider	  that	  by	  doubling	  the	  parameter	   	  in	  
Equation	  (6),	  any	  fit	  by	  this	  new	  model	  to	  a	  given	  concentration	  curve	  will	  yield	  
	  and	   	  exactly	  half	  of	  that	  predicted	  by	  the	  model	  valuations	  utilized	  in	  this	  
project.	  Thus,	  with	  an	  AIF	  that	  is	  not	  a	  good	  approximation	  of	  plasma	  contrast,	  the	  
model	  fitting	  stage	  may	  generate	  non-­‐physiologic	  free	  parameters	  that	  would	  result	  
in	  a	  voxel’s	  rejection	  (for	  instance,	  a	  “true”	   	  valued	  half	  of	  that	  utilized	  here	  would	  
result	  in	  the	  rejection	  of	  all	  voxels	  with	  “true”	   	  ranged	  0.5-­‐1).	  This	  is	  a	  limitation	  
intrinsic	  to	  utilizing	  population-­‐derived	  AIF:	  individual	  variation	  is	  lost,	  thus	  –	  in	  
addition	  to	  lower	  voxel	  matching	  rates	  if	  the	  AIF	  is	  not	  reasonably	  close	  to	  “true”-­‐-­‐	  
accuracy	  in	   	  calculations	  is	  reduced.	  	  
	  
This	  potential	  source	  of	  error	  is	  accounted	  for	  in	  this	  study	  through	  the	  use	  of	  an	  
automated	  means	  for	  supplying	  the	  contrast	  bolus,	  and	  by	  assuming	  that	  a	  patient’s	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physiology	  will	  not	  change	  sufficiently	  to	  alter	  the	  shape	  of	  the	  bolus	  between	  
studies.	  Because	  this	  study	  considers	  percentage	  change	  between	  two	  time	  points,	  it	  
is	  assumed	  that	  any	  error	  produced	  by	  an	  incorrect	  AIF	  in	  analysis	  will	  be	  
sufficiently	  reproduced	  at	  the	  second	  time	  point	  as	  to	  be	  negligable.	  Considering	  the	  
non-­‐linearity	  of	  the	  Tofts	  model,	  this	  may	  not	  be	  a	  reasonable	  assumption.	  Note	  that	  
this	  issue	  is	  not	  addressed	  in	  previous	  studies.	  
	  
Alternatives	  to	  using	  a	  population	  derived	  AIF	  are	  to	  create	  a	  patient	  specific	  AIF	  
based	  on	  the	  first	  pass	  of	  contrast	  through	  an	  artery	  in	  the	  imaged	  field	  of	  view.	  	  	  An	  
automated	  technique	  for	  this	  was	  first	  described	  in	  200146	  and	  this	  technique	  has	  
been	  used	  in	  similar	  studies	  performed	  at	  the	  NCI20.	  	  However,	  the	  assumptions	  
used	  in	  the	  T1	  mapping	  scheme	  described	  above	  do	  not	  hold	  at	  gadolinium	  
concentrations	  normally	  found	  in	  arterial	  blood	  (at	  high	  concentrations	  the	  signal	  
intensity	  can	  saturate	  due	  to	  T2*	  effects).	  	  This	  was	  shown	  in	  the	  reference	  
discussed	  in	  the	  next	  paragraph.	  	  Subsequent	  errors	  in	  the	  AIF	  would	  result	  in	  the	  
same	  problems	  described	  above.	  	  
	  
Another	  alternative	  solution	  is	  to	  administer	  a	  small	  bolus	  of	  contrast	  (roughly	  10%	  
of	  the	  normal	  dose)	  and	  use	  this	  bolus	  to	  prospectively	  construct	  an	  AIF	  scaled	  to	  a	  
subsequent	  injection47.	  This	  technique	  has	  not,	  to	  our	  knowledge,	  been	  applied	  in	  
any	  published	  studies.	  	  	  Additionally,	  the	  authors	  who	  describe	  this	  technique	  did	  
not	  calculate	  the	  AIF	  using	  T1	  mapping	  techniques.	  	  Instead,	  they	  assumed	  that	  
contrast	  equation	  scaled	  linearly	  with	  relative	  signal	  enhancement	  (i.e.	  a	  doubling	  in	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signal	  intensity	  equaled	  a	  doubling	  in	  concentration)	  which	  is	  not	  quantatively	  
accurate.	  	  It	  is	  not	  clear	  how	  this	  assumption	  affects	  the	  calculated	  AIF	  and	  thus	  the	  
subsequent	  calculations.	  
	  
A	  third	  alternative	  is	  to	  utilize	  a	  reference	  method	  first	  described	  by	  Yankeelov48.	  	  In	  
this	  method,	  time	  enhancement	  curves	  are	  measured	  in	  a	  non-­‐neoplastic	  tissue	  such	  
as	  pectoralis	  muscle.	  	  Using	  assumed	  values	  of	   	  and	  kep	  for	  these	  tissues,	  the	  
Tofts	  model	  is	  solved	  for	  the	  AIF.	  	  This	  AIF	  is	  then	  used	  for	  analysis	  of	  the	  tumor	  
enhancement	  curve.	  	  Potential	  problems	  with	  this	  method	  mirror	  those	  of	  using	  a	  
population	  AIF	  in	  that	  it	  is	  not	  known	  how	  constant	  pectoralis	  muscle	   	  is	  
throughout	  the	  population.	  	  Additionally,	  these	  values	  may	  be	  affected	  by	  
chemotherapy	  and	  change	  over	  time.	  	  To	  account	  for	  this	  some	  authors	  have	  
modified	  the	  technique	  to	  report	  a	  tumor	   	  scaled	  to	  that	  of	  the	  reference	  
tissue49	  and	  perform	  ROC	  analyses	  based	  on	  those	  values.	  	  This	  makes	  comparing	  
perfusion	  results	  from	  patient	  to	  patient	  and	  from	  study	  to	  study	  difficult	  because	  
the	  reported	  parameter	  is	  not	  tumor	  specific.	  	  An	  additional	  problem	  with	  the	  
reference	  method	  is	  that	  for	  this	  study	  the	  physical	  geometry	  of	  the	  breast	  coil	  used	  
in	  the	  MRI	  exam	  results	  in	  decreased	  signal	  to	  noise	  in	  the	  muscles	  due	  to	  their	  
posterior	  location.	  	  Reference	  imaging	  is	  more	  practical	  when	  studying	  neoplasms	  
like	  cervical	  and	  prostate	  cancer	  where	  reference	  muscles	  are	  located	  near	  the	  
center	  of	  the	  field	  of	  view.	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A	  second	  limitation	  in	  the	  computation	  algorithm	  is	  the	  technique	  used	  for	  T1	  
mapping.	  	  Equation	  (9)	  above	  should	  produce	  an	  accurate	  calculation	  of	  T1	  in	  ideal	  
circumstances.	  	  The	  B1	  field	  must	  be	  homogenous	  throughout	  the	  entire	  field	  of	  
view,	  the	  longitudinal	  magnetization	  must	  be	  in	  steady	  state,	  and	  the	  transverse	  
magnetization	  must	  be	  completely	  spoiled	  before	  each	  repeated	  excitation.	  	  More	  
sophisticated	  techniques	  have	  been	  developed	  that	  take	  these	  potential	  confounders	  
into	  consideration50.	  The	  study	  scan	  protocol	  did	  not	  allow	  for	  this	  type	  of	  analysis.	  
	  
Additionally,	  T1	  histogram	  analysis	  revealed	  a	  large	  variation	  in	  measured	  T1	  
values	  across	  structures	  that	  should	  be	  relatively	  homogenous,	  such	  as	  adipose	  
tissue	  in	  the	  breast	  (for	  an	  example,	  see	  Figure	  7).	  	  This	  suggests	  that	  the	  pre-­‐
contrast	  reference	  series,	  obtained	  a	  low	  flip	  angle,	  may	  have	  had	  insufficient	  signal	  
to	  noise	  to	  be	  accurately	  used	  in	  the	  analysis.	  	  For	  this	  reason,	  we	  performed	  most	  of	  
our	  analyses	  on	  mean	  tumor	  regions	  of	  interest	  as	  opposed	  to	  voxel	  by	  voxel	  
analyses.	  	  Averaging	  signal	  from	  all	  the	  voxels	  in	  the	  tumor	  resulted	  in	  baseline	  T1	  
measurements	  more	  in	  line	  with	  those	  in	  the	  literature.	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Figure	  7	  Histogram	  of	  calculated	  initial	  T1	  over	  all	  voxels	  in	  a	  volume	  of	  interest	  placed	  over	  breast	  
adipose	  tissue	  (true	  adipose	  T1	  is	  approximately	  300ms)	  
The	  performance	  of	  each	  criterion	  used	  for	  prediction	  of	  response	  to	  therapy	  also	  
necessitates	  remarks.	  In	  particular,	  the	  Padhani	  criterion	  is	  extremely	  difficult	  to	  
justify.	  In	  carefully	  considering	  their	  study	  design,	  note	  that	  Padhani	  et.	  al.	  rejected	  
all	  voxels	  that	  yielded	   	  greater	  than	  0.5/sec	  because	  valuation	  above	  that	  cutoff	  
was	  said	  to	  have	  an	  unclear	  physiological	  meaning.	  This	  arbitrary	  cutoff	  necessarily	  
sets	  an	  upper-­‐bound	  on	  the	  possible 	  range,	  and	  thus	  effects	  their	  receiver	  
operating	  characteristic	  analysis.	  Additionally,	  the	  AIF	  they	  chose	  for	  their	  study	  is	  
the	  same	  as	  that	  for	  the	  original	  Tofts	  model	  and	  given	  in	  Equation	  (4).	  Because	  the	  
Tofts	  AIF	  does	  not	  accurately	  reflect	  the	  true	  concentration	  of	  contrast	  in	  plasma,	  
the	  absolute	  value	  of	  the	   	  generated	  via	  their	  method	  may	  vary	  with	  true	   ,	  
but	  it	  may	  not	  be	  accurately	  valued.	  Thus,	  their	  use	  of	  a	  cutoff	  is	  highly	  questionable;	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without	  it,	  the	  range	  trends	  reported	  in	  their	  results	  would	  be	  much	  more	  
susceptible	  to	  noise.	  
	  
That	  the	  Ah-­‐See	  and	  Yu	  criteria	  were	  both	  able	  to	  correctly	  predict	  all	  non-­‐
responders	  while	  failing	  to	  accurately	  do	  the	  same	  for	  positive	  responders	  is	  
interesting.	  One	  possible	  explanation	  is	  that	  each	  of	  their	  criteria	  was	  applied	  after	  
completion	  of	  the	  second	  cycle	  of	  neoadjuvant	  chemotherapy.	  In	  this	  thesis,	  they	  are	  
applied	  after	  the	  first.	  Presumably,	  with	  more	  time,	  the	  responders	  could	  reach	  the	  
cutoffs	  reported.	  Another	  explanation	  is	  simply	  that	  neither	  criterion	  was	  reported	  
to	  have	  100%	  sensitivity.	  Thus,	  with	  our	  limited	  data,	  it	  is	  impossible	  to	  tell	  if	  this	  
failure	  represents	  a	  significant	  difference.	  
	  
Finally,	  the	  performance	  of	  our	  data-­‐generated	  cutoff	  appears	  promising.	  By	  judging	  
the	  performance	  of	  each	  criterion	  to	  how	  closely	  it’s	  determinant	  value	  is	  to	  one	  that	  
would	  accurately	  segment	  the	  two	  populations,	  ours	  performed	  best.	  That	  said,	  had	  
imaging	  been	  performed	  at	  two	  cycles	  instead	  of	  one,	  the	  accuracy	  of	  Ah-­‐See	  and	  Yu	  
may	  have	  been	  higher.	  On	  the	  question	  of	  the	  difference	  between	  the	  values	  of	  our	  
cutoff	  and	  Ah-­‐See’s,	  there	  are	  several	  possible	  reasons.	  Specifically,	  contributions	  to	  
the	  repeatability	  range	  accounted	  for	  by	  Ah-­‐See’s	  method,	  but	  not	  ours,	  are	  imaging	  
parameter	  inaccuracies,	  errors	  of	  slice	  selection,	  and	  differences	  in	  coil	  placement	  
between	  studies	  (among	  others).	  Conversely,	  our	  data	  (unlike	  Ah-­‐See’s)	  were	  
generated	  with	  heterogeneous	  imaging	  parameters.	  	  With	  both	  of	  these	  important	  
differences	  in	  mind,	  note	  that	  Ah-­‐See’s	  cutoff	  falls	  within	  one	  standard	  of	  deviation	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of	  our	  average	  value.	  It	  is	  certainly	  plausible	  that	  their	  value	  could	  just	  as	  easily	  have	  
been	  generated	  on	  their	  data	  using	  our	  method.	  On	  examination	  of	  Ah-­‐See’s	  paper,	  it	  
appears	  possible	  to	  separate	  data	  with	  100%	  accuracy	  into	  three	  categories:	  those	  
with	  change	  of	  median	   	  below	  –43.7%	  (our	  mean	  value,	  minus	  one	  standard	  
deviation)	  as	  predicted	  pathological	  responders,	  those	  with	  change	  of	  median	   	  
above	  -­‐35.1%	  (our	  mean	  value	  plus	  one	  standard	  deviation)	  as	  predicted	  
pathological	  non-­‐responders,	  and	  those	  few	  in-­‐between	  needing	  further	  evaluation.	  
This	  is	  all	  speculative	  but	  our	  results	  do	  suggest	  it	  is	  possible	  to	  generate	  a	  suitable	  
repeatability	  range	  by	  segmentation	  of	  a	  single	  lesion.	  More	  data	  are	  needed	  for	  any	  
meaningful	  conclusions.	  
	  
Considering	  the	  results	  presented	  here,	  there	  are	  several	  potential	  interesting	  
avenues	  for	  future	  research.	  As	  patients	  continue	  to	  be	  enrolled	  in	  the	  Yale/BrUOG	  
study,	  the	  analysis	  begun	  and	  described	  as	  part	  of	  this	  thesis	  can	  be	  continued	  to	  
better	  elucidate	  the	  validity	  of	  the	  retrospectively-­‐derived	  criteria.	  Additional	  
patients	  may	  also	  influence	  our	  measured	  repeatability	  range.	  It	  should	  also	  be	  
noted	  that	  DCLab	  was	  written	  to	  be	  extended	  and	  modified,	  thus	  there	  is	  potential	  
for	  its	  future	  utilization	  in	  research	  on	  novel	  targets	  and	  via	  novel	  models.	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